Mayflower Financial Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Mayflower Financial Advisors’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.8K	Hold	12,559	–	–	﹤0.01%	497
2026 Q1	$21.9K	Hold	12,559	–	–	﹤0.01%	443
2025 Q4	$21.9K	Buy	+12,559	New	+$27.7K	﹤0.01%	414
2024 Q1	–	Sell	-2,579	Closed	-$15.8K	–	360
2023 Q4	$15.8K	Hold	2,579	–	–	﹤0.01%	340
2023 Q3	$12K	Hold	2,579	–	–	﹤0.01%	339
2023 Q2	$13.8K	Hold	2,579	–	–	﹤0.01%	354
2023 Q1	$25.4K	Hold	2,579	–	–	﹤0.01%	343
2022 Q4	$48.3K	Hold	2,579	–	–	0.01%	335
2022 Q3	$53K	Hold	2,579	–	–	0.01%	317
2022 Q2	$54K	Hold	2,579	–	–	0.01%	315
2022 Q1	$111K	Buy	2,579 +33	+1%	+$1.49K	0.01%	341
2021 Q4	$152K	Sell	2,546 -24	-0.9%	-$1.92K	0.02%	329
2021 Q3	$220K	Hold	2,570	–	–	0.03%	304
2021 Q2	$286K	Buy	2,570 +36	+1%	+$3.46K	0.04%	253
2021 Q1	$282K	Buy	2,534 +111	+5%	+$14.6K	0.04%	237
2020 Q4	$257K	Buy	+2,423	New	+$323K	0.04%	224

Other funds holding INO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Mayflower Financial Advisors's INO Position: Q2 2026 in Review

Mayflower Financial Advisors held its Inovio Pharmaceuticals (INO) position steady in Q2 2026 at 12,559 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #497.

Mayflower Financial Advisors first reported a position in INO in Q4 2020 and has held it in 16 quarters since. The position peaked at $286K in Q2 2021. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

Mayflower Financial Advisors held 12,559 shares of Inovio Pharmaceuticals worth $13.8K as of Q2 2026.
Mayflower Financial Advisors left its Inovio Pharmaceuticals share count unchanged in Q2 2026.
Inovio Pharmaceuticals made up ﹤0.01% of Mayflower Financial Advisors's portfolio in Q2 2026, its #497 holding.
Mayflower Financial Advisors first reported a position in Inovio Pharmaceuticals in Q4 2020 and has held it in 16 quarters since.
Mayflower Financial Advisors's Inovio Pharmaceuticals position peaked at $286K in Q2 2021.
103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Mayflower Financial Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.